Immunomodulating Drugs for the Treatment of Cancer brings the most current information on these novel compounds to clinicians and scientists involved in the care of cancer patients.

Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of antitumor activity and a number of cancers. While there is a lot of literature published on these agents, until now there has been no textbook that provides a comprehensive resource for clinicians and researchers regarding these agents and their rapidly emerging role in cancer medicine.

The clinical applications of these agents are not limited to oncologists and hematologists, but also impact primary care doctors who care for these patients. Furthermore, new investigations are defining the role of these agents in non-malignant disorders as well.